Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01440998
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:57.714785+00:00
Published At
2018-04-05T00:00:00+00:00
Record Updated At
2018-04-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-04-05"
protocolSection.identificationModule.nctId
"NCT01440998"
protocolSection.identificationModule.officialTitle
"Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Uterine Corpus Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.